HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term protection. If this yearly injection is approved and widely implemented, it could mark a major shift in global HIV prevention efforts. It has the potential to significantly reduce new HIV infections, particularly in communities with high transmission rates.